-
The eighth batch of centralized procurement of large varieties game: Pfizer and others compete for the 60 billion market!
Time of Update: 2023-02-01
Among the multinational original research enterprises, Pfizer, Sanofi, Merck, Lundbeck, AstraZeneca, Eisai and other enterprises are listed, of which Pfizer has the largest number of products, and 3 varieties are to be included, with cefoperazone sulbactam injection and voriconazole injection having a high market share.
-
WuXi Biologics rises more than 6%! For a license-out deal with GSK
Time of Update: 2023-02-01
In addition to WuXi Biologics, companies with self-developed bispecific antibody technology platforms such as Harbour Biologics have also received hundreds of millions of dollars in transactions through external licensing and cooperation.
-
Industry: The pharmaceutical sector has low valuations and there are always opportunities in 2023
Time of Update: 2023-02-01
The medical device sector has been attracting much attention in the industry in recent years, and in 2022, there are a total of 5 pharmaceutical device companies listed on the Science and Technology Innovation Board, including United Imaging Medical, a leading enterprise of medical imaging equipment, Huada Intelligent Manufacturing of gene sequencing equipment, micro-electrophysiology of the head enterprise of electrophysiological equipment, and Shanwaishan, a head enterprise of hemodialysis machines, etc.
-
This pharmaceutical stock rose slightly on the 9th, and at the beginning of the year, it was investigated by more than 100 institutions for an insomnia drug
Time of Update: 2023-02-01
Jingxin Pharmaceutical replied to investors on the interactive platform on January 3 that didacinib is still in the comprehensive review stage, and the company will continue to pay attention to the approval dynamics and announce the relevant approval progress in accordance with the information disclosure requirements.
-
Coenzyme Q10 was snapped up, and related concept stocks attracted attention!
Time of Update: 2023-02-01
In addition to King Dawei, it is reported that Lily shares said that orders for products including coenzyme Q10 have increased sharply recently, and the supply of products has exceeded demand, and the company has produced at full capacity by adjusting production lines.
-
On January 6, the net outflow of the pharmaceutical and biological sector exceeded 1.8 billion yuan
Time of Update: 2023-02-01
From the perspective of individual stocks, as of 14:15 on January 6, Goertek shares were sold more than 700 million yuan, and the net outflow of main funds such as Unigroup Guowei, Annie Shares, and Meiliyun ranked first.
-
The traditional Chinese medicine sector has changed! Kangyuan Pharmaceutical rose more than 6%, and Dong Ejiao rose nearly 5%
Time of Update: 2023-02-01
News on January 12, the traditional Chinese medicine sector changed, in terms of individual stocks, Kangyuan Pharmaceutical rose by more than 6%, and Dong'a Jiao rose by nearly 5%, in addition, Jianmin Group, Pian Zixi, Zhongsheng Pharmaceutical, etc.
-
Interpretation of the 14th Five-Year Plan for Emergency Medical Rescue
Time of Update: 2023-02-01
The main contents of the Plan Guided by the Thought on Socialism with Chinese Characteristics for a New Era, the Plan thoroughly implements the spirit of the Party, and makes systematic design and specific deployment of the overall requirements, basic principles, development goals, main tasks and safeguard measures for emergency medical rescue work during the 14th Five-Year Plan period.
-
Zhejiang will temporarily include 15 kinds of drugs in the scope of medical insurance payment from the 6th
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Medical security bureaus of cities and counties (cities and districts): In order to effectively respond to the new changes in the situation of the new coronavirus infection epidemic and the new challenges of prevention and control, meet the drug needs of patients and reduce the medical burden of patients, with the approval of the National Medical Security Administration, 15 drugs such as "compound aminophenolamine capsules" were temporarily included in the scope of medical insurance payment (see annex).
-
In 2022, the total amount of chromatography winning bids exceeded 240 million yuan, involving 48 brands
Time of Update: 2023-02-01
According to incomplete statistics of Chemical Instrument Network, there are 1,016 chromatography related entries on the Chinese government procurement network in 2022, 448 sets of winning chromatographic instruments, and the total amount of winning the bid exceeds 240 million yuan, involving 48 brands at home and abroad, and 210 companies participate in procurement.
-
Pharmaceutical companies pay close attention to the diabetes drug market, and the research and development of new drugs is accelerating
Time of Update: 2023-02-01
【Pharmaceutical Network Market Analysis】The field of diabetes treatment has always been one of the hot spots in the global pharmaceutical field, and with the acceleration of the global aging process a
-
Disease control experts: At this stage, it is difficult for XBB strains to form a large-scale epidemic
Time of Update: 2023-02-01
XBB, an Omicron variant circulating in Europe and the United States with enhanced immune evasion ability, as it was detected in people quarantined in China, XBB quickly attracted attention, and in a series of branches of XBB, the most noteworthy is the "XBB.
-
Today, the pharmaceutical industry has a net outflow of 2 billion yuan, with Hanyu Pharmaceutical, Meinian Health and Huahai Pharmaceutical in the lead
Time of Update: 2023-02-01
According to the statistics of capital flow data, among the net outflow of funds from the pharmaceutical and biological industry, there are 8 stocks with a net outflow of more than 50 million yuan, namely Hanyu Pharmaceutical, Meinian Health, Huahai Pharmaceutical, Fosun Pharma, Watson Biotechnology, Xingqi Eye Medicine, Nuotai Biotechnology, and Shanghai RAAS.
-
The "take medicine" market has returned? More than 200 pharmaceutical-themed funds achieved positive returns
Time of Update: 2023-02-01
According to Databao's statistics, in the past five trading days (December 29 to January 5), about 139 listed companies in Shanghai and Shenzhen have been investigated by institutions.
-
How to improve the treatment capacity of patients in primary health institutions in China? ——Authoritative experts interpret hot issues in epidemic prevention
Time of Update: 2023-02-01
How to improve the treatment capacity of patients in primary health institutions in China and the treatment capacity of severe new crown disease in rural areas?
How to improve the treatment capacity of patients in primary health institutions in China and the treatment capacity of severe new crown disease in rural areas?
-
The policy of making good profits in traditional Chinese medicine has frequently increased, and the pharmaceutical packaging industry has also attracted the attention of investors
Time of Update: 2023-02-01
【Pharmaceutical Network Market Analysis】Recently, some investors asked Haishun New Materials on the investor interactive platform, saying that the country is now vigorously promoting traditional Chine
-
The profitability of the API sector has gradually recovered, and enterprises have actively promoted industrial upgrading
Time of Update: 2023-02-01
【Pharmaceutical Network Market Analysis】 With the continuous change of human disease spectrum, the increasing total population, the increasing aging degree of various countries, the acceleration of urbanization, the enhancement of people's awareness of health care and the further improvement of the medical insurance system, the market size of the global pharmaceutical industry is increasing year by year.
-
Interpretation of the "Novel Coronavirus Infection Severe Diagnosis and Treatment Plan (Trial Fourth Edition)"
Time of Update: 2023-02-01
In order to further improve the medical treatment of severe cases of novel coronavirus infection and effectively improve the level of standardized and homogeneous diagnosis and treatment, the Nationa
-
In January, pharmaceutical investment returned to normal, and the pharmaceutical sector of Hong Kong stocks recovered, and many stocks rose sharply
Time of Update: 2023-02-01
According to the data, Akeso Biopharma is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody new drugs.
According to the data, Akeso Biopharma is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody new drugs.
-
88 stocks traded in large quantities! Hengrui Pharmaceutical and other three pharmaceutical companies ranked first in terms of turnover
Time of Update: 2023-02-01
According to statistics, in terms of revenue in 2020, Kaileying is a large-scale commercial-stage chemical drug CDMO company in China.
According to statistics, in terms of revenue in 2020, Kaileying is a large-scale commercial-stage chemical drug CDMO company in China.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
